10x Genomics Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shar...
September 15 2020 - 4:25PM
10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced
the closing of its public offering of 4,600,000 shares of its Class
A common stock, which included the exercise in full of the
underwriters’ option to purchase 600,000 additional shares of its
Class A common stock, at a public offering price of $110.00 per
share. Including the option exercise, the aggregate gross proceeds
from the offering were $506 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by the Company. All of the shares were offered by the Company.
J.P. Morgan Securities LLC, BofA Securities and Cowen and
Company, LLC acted as lead joint book-running managers for the
offering. Stifel and William Blair acted as co-managers for
the offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission, and became
effective on September 10, 2020. The offering was made only by
means of a prospectus. Copies of the final prospectus may be
obtained by contacting: J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at 1-866-803-9204 or by email at
prospectus-eq_fi@jpmchase.com; BofA Securities, NC1-004-03-43, 200
North College Street, 3rd floor, Charlotte, NC 28255-0001,
Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com and Cowen and Company, LLC,
c/o Broadridge Financial Solutions, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
ContactsInvestors:investors@10xgenomics.com
Media:media@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2023 to Apr 2024